secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2022-10-28T23:59:59+00:00
Accession:  0001551152-22-000038
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie Q3 adj. EPS $3.66 (+29.3%) on revenue $14.8B; raises 2023 dividend 5%
----------------------------------------------------------------------------

- GAAP diluted EPS $2.21 (+24.2%); adjusted diluted EPS $3.66 (+29.3%), includes $0.02 IPR&D hit.
- Total net revenues $14.812B (+3.3% reported, +5.4% operational). Immunology $7.651B (+14.6%).
- U.S. Humira $4.956B (+7.4%); international Humira $603M (-25.9%) due to biosimilars; Skyrizi $1.397B, Rinvoq $695M.
- Hematologic oncology $1.650B (-11.7%) with Imbruvica $1.135B (-17.4%); Neuroscience $1.672B (+6.7%), Aesthetics $1.301B (+4.0%).
- Narrows FY2022 adj. EPS guidance to $13.84-$13.88 (from $13.76-$13.96); announces 5% dividend increase starting Feb 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115222000038/0001551152-22-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115222000038/abbv-20221028.htm
  HTML page:      https://secwatch.observer/filing/0001551152-22-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer